# EDGAR Filing Document

**Accession Number:** 0001888014
**File Stem:** 0001104659-23-000530
**Filing Date:** 2023-1
**Character Count:** 74066
**Document Hash:** 5865b71d618f8699b0cb9e55458fed13
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-000530.hdr.sgml**: 20230104

**ACCESSION NUMBER**: 0001104659-23-000530

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 77

**CONFORMED PERIOD OF REPORT**: 20220630

**FILED AS OF DATE**: 20230104

**DATE AS OF CHANGE**: 20230103

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AKANDA CORP.
- **CENTRAL INDEX KEY:** 0001888014
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41324
- **FILM NUMBER:** 23504232

**BUSINESS ADDRESS:**
- **STREET 1:** 1A, 1B LEAROYD ROAD
- **CITY:** NEW ROMNEY
- **STATE:** X0
- **ZIP:** TN28 8XU
- **BUSINESS PHONE:** 442034889514

**MAIL ADDRESS:**
- **STREET 1:** 77 KING STREET WEST, SUITE 400
- **STREET 2:** C/O DENTONS CANADA LLP
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 0A1

?xml version='1.0' encoding='UTF-8'?

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

------

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of** **January 2023**

**Commission File Number: 001-41324**

## AKANDA CORP.
**(Registrant's Name)**

------

**1a, 1b Learoyd Road**

**New Romney TN28 8XU, United Kingdom**

**(Address of Principal Executive Office)**

------

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

**INFORMATION CONTAINED IN THIS FORM 6-K REPORT**

This Report of Foreign Private Issuer on Form 6-K ("Form 6-K") of Akanda Corp. (the "Company") contains the Company's unaudited interim condensed consolidated financial statements for the six months ended June 30, 2022 and 2021.

**Exhibit Index**

The unaudited interim condensed consolidated financial statements for the Company for the six months ended June 30, 2022 and 2021 are furnished as Exhibit 99.1 to this Form 6-K.

Exhibit 99.1 [Unaudited Condensed Consolidated Interim Financial Statements as of and for the six month periods ended June 30, 2022 and 2021.](akan-20220630xex99d1.htm)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| **AKANDA CORP.** | **AKANDA CORP.** | **AKANDA CORP.** |
| By | : | /s/ Katie Field |
| Name | : | Katie Field  |
| Title | : | Executive Director |

---

Date: January 3, 2023

## Exhibit 99.1

?xml version='1.0' encoding='UTF-8'?

0.040.010.100.132683544413129212268354440.03000.030013129212 **Exhibit 99.1**

**Akanda Corp.**

**Unaudited Condensed Consolidated Statements of Financial Position**

**(Expressed in US Dollars)**

---

| | | | |
|:---|:---|:---|:---|
|  | <br>**Note** | **June 30,** <br>**2022** | **December 31,** <br>**2021** |
| **ASSETS** |  |  |  |
| **Current** |  |  |  |
| &nbsp;&nbsp;Cash |  | $3930702 | $3495390 |
| &nbsp;&nbsp;Cash held in trust | 4 | 472512 |  |
| &nbsp;&nbsp;Trade and other receivables | 5 | 726865 | 242357 |
| &nbsp;&nbsp;Prepayments |  | 380837 | 107759 |
| &nbsp;&nbsp;Biological assets |  | 198631 |  |
| &nbsp;&nbsp;Inventory |  | 895774 |  |
| &nbsp;&nbsp;Financial asset measured at FVTPL | 8 | 337145 |  |
| **Total Current Assets** |  | 6942466 | 3845506 |
| **Non-Current** |  |  |  |
| &nbsp;&nbsp;Property, plant and equipment | 9 | 12608287 | 1897748 |
| &nbsp;&nbsp;Intangible assets | 11 | 23446256 | 259102 |
| &nbsp;&nbsp;Loan Receivable | 12 | 485272 | 134770 |
| &nbsp;&nbsp;Right-of-use assets | 10 |  | 1908877 |
| **Total Non-Current assets** |  | 36539815 | 4200497 |
| **Total Assets** |  | $43482281 | $8046003 |
| **LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)** |  |  |  |
| **Current** |  |  |  |
| &nbsp;&nbsp;Trade and other payables |  | $4491284 | $680328 |
| &nbsp;&nbsp;Lease liability | 13 |  | 439709 |
| &nbsp;&nbsp;Loans and borrowings | 14 | 1262785 | 432201 |
| &nbsp;&nbsp;Secured convertible debenture | 15 and 16 |  | 6716190 |
| &nbsp;&nbsp;Holdback payable | 4 | 400000 |  |
| &nbsp;&nbsp;Due to related party |  | 117625 |  |
| **Total Current Liabilities** |  | 6271694 | 8268428 |
| **Non-Current** |  |  |  |
| &nbsp;&nbsp;Lease liability | 13 |  | 1978997 |
| &nbsp;&nbsp;Loans and borrowings | 14 | 2570127 |  |
| **Total Non-Current Liabilities** |  | 2570127 | 1978997 |
| **Total liabilities** |  | 8841821 | 10247425 |
| **Shareholders' Equity (Deficit)** |  |  |  |
| &nbsp;&nbsp;Share capital | 15 | 47101209 | 7255695 |
| &nbsp;&nbsp;Contributed surplus |  | 576340 |  |
| &nbsp;&nbsp;Other reserves |  | 21051 | 3618670 |
| &nbsp;&nbsp;Accumulated deficit |  | (12024032) | (13293889) |
| &nbsp;&nbsp;Accumulated other comprehensive income |  | (1034108) | 218102 |
| **Total Shareholders' Equity (Deficit)** |  | 34640460 | (2201422) |
| **Total Liabilities and Shareholders' Deficit** |  | $43482281 | $8046003 |
| Subsequent Events (Note 18) |  |  |  |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**Akanda Corp.**

**Unaudited Condensed Consolidated Statements of Loss and Comprehensive Loss**

**(Expressed in US Dollars)**

---

| | | | |
|:---|:---|:---|:---|
|  | | **Six months ended** | **Six months ended** |
|  | | **June 30,**  | **June 30,**  |
|  | <br>**Note** | **2022** | **2021** |
| **Sales** |  | $73096 | $3935 |
| Cost of sales | 7 | 12870 | 5849 |
| **Gross Profit (Loss) before gain on change in fair value of biological assets** |  | 60226 | (1914) |
| Gain on change in fair value of biological assets |  | 33078 |  |
| **Gross Profit (Loss)** |  | 93304 | (1914) |
| **Operating expenses** |  |  |  |
| &nbsp;&nbsp;Depreciation and amortization | 9, 10, 11 | 1511138 |  |
| &nbsp;&nbsp;Consulting and professional fees |  | 2366997 | 142188 |
| &nbsp;&nbsp;Personnel expenses |  | 3782727 |  |
| &nbsp;&nbsp;Share based payment expenses to social development trust | 15 | 2174908 |  |
| &nbsp;&nbsp;General and administrative expenses |  | 1175647 | 1401 |
| **Total operating expenses** |  | 11011417 | 143589 |
| **Operating loss** |  | (10918113) | (145503) |
| **Other (expense) income:** |  |  |  |
| &nbsp;&nbsp;Finance income |  | 747 |  |
| &nbsp;&nbsp;Finance expense |  | (36606) |  |
| &nbsp;&nbsp;Foreign exchange loss, net |  | (180990) | (969) |
| &nbsp;&nbsp;Gain on bargain purchase |  | 12760356 |  |
| &nbsp;&nbsp;Other income | 4 | 207 | 55 |
| &nbsp;&nbsp;Change in fair value of financial assets measured at FVTPL | 8 | (472311) |  |
|  |  | 12071403 | (914) |
| Net income (loss) from continuing operations |  | 1153290 | (146417) |
| Loss from discontinued operations | 5 | (3747034) | (1525935) |
| **Net loss** |  | $(2593744) | $(1672352) |
| Translation adjustment |  | (1019498) | (184492) |
| Comprehensive loss |  | $(3613242) | $(1856844) |
| Earnings (loss) per share from continuing operations – basic and diluted | 15 | $0.04 | $(0.01) |
| Loss per share - basic and diluted | 15 | $(0.10) | $(0.13) |
| Weighted average common shares outstanding | 15 | 26835444 | 13129212 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**Akanda Corp.**

**Unaudited Condensed Consolidated Statements of Shareholders' Equity (Deficit)**

**(Expressed in US Dollars)**

**For the Six Months Ended June 30, 2022**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | <br>**Note** | <br>**Share**<br>**capital** | <br>**Contributed**<br>**surplus – Stock** <br>**Based Compensation** | <br>**Other**<br>**reserves** | <br>**Accumulated**<br>**deficit** | **Accumulated**<br>**Other** <br>**comprehensive**<br>**loss** | <br>**Total** |
| Balance, December 31, 2020 |  | $159 | $— | $21053 | $(5162692) | $108060 | $(5033420) |
| Net loss |  |  |  |  | (1672352) |  | (1672352) |
| Translation adjustment |  |  |  |  |  | (184492) | (184492) |
| Balance, June 30, 2021 |  | $159 | $— | $21053 | $(6835044) | $(76432) | $(6890264) |
| Balance, December 31, 2021 |  | $7255695 | $— | $3618670 | $(13293889) | $218102 | $(2201422) |
| Issuance of shares for Holigen Acquisition | 4 and 14 | 16131000 |  |  |  |  | 16131000 |
| Issuance of shares to ASDT | 14 | 2174908 |  |  |  |  | 2174908 |
| Issuance of shares from private placement | 14 | 298684 |  |  |  |  | 298684 |
| Issuance of shares from IPO | 14 | 14682078 |  |  |  |  | 14682078 |
| Issuance of shares upon conversion of note | 14 and 15 | 6559000 |  |  |  |  | 6559000 |
| Loss of control of Bophelo Bio | 5 | (156) |  | (3597619) | 3863601 | (232712) | 33114 |
| Stock-based compensation | 14 |  | 576340 |  |  |  | 576340 |
| Net loss |  |  |  |  | (2593744) |  | (2593744) |
| Translation adjustment |  |  |  |  |  | (1019498) | (1019498) |
| Balance, June 30, 2022 |  | $47101209 | $576340 | $21051 | $(12024032) | $(1034108) | $34640460 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**Akanda Corp.**

**Unaudited Condensed Consolidated Statements of Cash Flows**

**(Expressed in US Dollars)**

---

| | | | |
|:---|:---|:---|:---|
|  | | **Six months ended** | **Six months ended** |
|  | | **June 30,**  | **June 30,**  |
|  | <br>**Note** | **2022** | **2021** |
| **Cash flows from operating activities:** |  |  |  |
| Net income (loss) from continuing operations |  | $1153290 | $(146417) |
| Net loss from discontinued operations |  | (3747034) | (1525935) |
| Net income (loss) |  | (2593744) | (1672352) |
| *Adjustments for non-cash items:* |  |  |  |
| &nbsp;&nbsp;Loss on loss of control of Bophelo Bio, net of cash surrendered |  | 2571054 |  |
| &nbsp;&nbsp;Gain on bargain purchase |  | (12760356) |  |
| &nbsp;&nbsp;Share based payments to social development trust | 15 | 2174908 |  |
| &nbsp;&nbsp;Depreciation and amortization | 9, 10, 11 | 1685038 | 152421 |
| &nbsp;&nbsp;Change in fair value of financial asset at fair value through profit or loss |  | 472311 |  |
| &nbsp;&nbsp;Stock-based compensation | 15 | 576340 |  |
| &nbsp;&nbsp;Non-cash interest expense |  | 122829 | 144747 |
| *Working capital adjustments (net of amounts acquired/disposed):* |  |  |  |
| &nbsp;&nbsp;Trade and other receivables |  | (118397) | (4959) |
| &nbsp;&nbsp;Prepayments |  | (932981) | 109855 |
| &nbsp;&nbsp;Inventory |  |  | 625 |
| &nbsp;&nbsp;Trade and other payables |  | 330065 | 248545 |
| &nbsp;&nbsp;Increase in due to related parties |  | 119212 |  |
| **Cash flows used in operating activities** |  | (8353721) | (1021118) |
| **Cash flows from investing activities:** |  |  |  |
| &nbsp;&nbsp;Acquisition of Holigen, net of cash acquired and holdback |  | (2366593) |  |
| &nbsp;&nbsp;Purchase of financial assets (refer to note 8) |  | (801160) |  |
| &nbsp;&nbsp;Additions to property, plant and equipment | 9 | (263391) | (545870) |
| &nbsp;&nbsp;Cash surrendered on loss of control of Bophelo Bio Sciences (refer to note 5) |  | (800794) |  |
| **Cash flows used in investing activities** |  | (4231938) | (545870) |
| **Cash flows from financing activities:** |  |  |  |
| &nbsp;&nbsp;Proceeds from IPO, net of costs |  | 14654593 |  |
| &nbsp;&nbsp;Proceeds from private placement, net of costs |  | 278482 |  |
| &nbsp;&nbsp;Advances from related party |  |  | 37812 |
| &nbsp;&nbsp;Loans received |  | 495665 | 3988898 |
| &nbsp;&nbsp;Loans repaid |  | (189892) |  |
| &nbsp;&nbsp;Lease payments |  | (596522) | (530811) |
| **Cash flows provided by financing activities** |  | 14642326 | 3495899 |
| **Net increase in cash and cash equivalents** |  | 2056667 | 1928909 |
| Effects of exchange rate changes on cash and cash equivalents |  | (1148913) | 24922 |
| Cash and cash equivalents at the beginning of the period |  | 3495460 | 13504 |
| Cash and cash equivalents at the end of the period |  | $4403214 | $1967335 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**Akanda Corp.**

**Notes to the Unaudited Condensed Consolidated Financial Statements**

**(Expressed in US Dollars)**

&nbsp;&nbsp;&nbsp;&nbsp;**1.** **Nature of Operations and Going Concern** 

Akanda Corp. (the "Company") is domiciled in Canada and was incorporated on July 16, 2021. The Company's registered office is 77 King Street West, Suite 400, Toronto-Dominion Centre, Toronto Canada, Ontario, M5K 0A1.

Prior to the liquidation event on July 15, 2022 described below, the Company, through its indirectly held subsidiary, Bophelo Bio Science and Wellness (Pty) Ltd. is in the business of cultivating and manufacturing cannabis biomass and medical cannabis products in Lesotho (specifically near Ts'akholo, in the Mafeteng district of the Kingdom of Lesotho, Southern Africa), for export to international markets. At June 30, 2022, the Company determined that it no longer controlled Bophelo Bio Science and Wellness (Pty) Ltd. as a result of the insolvent liquidation order signed by the Lesotho Court on July 15, 2022 (see note 5 and 17). As a result of the loss of control, the Company derecognized all assets and liabilities at their book values on June 30, 2022 and wrote down all balances receivable from the entity to nil. During the six months ended June 30, 2022, recorded a loss on loss of control of Bophelo Bio Science and Wellness (Pty) Ltd. of $2,338,342, which included $800,794 of cash held by Bophelo Bio Science and Wellness (Pty) Ltd. The Company accounted for the operating results of Bophelo Bio Science and Wellness (Pty) Ltd. as a discontinued operation during the six months ended June 30, 2022 and has reclassified the operating results of Bophelo Bio Science and Wellness (Pty) Ltd as a discontinued operation for the six months ended June 30, 2021. At the date of these condensed consolidated financial statements, the liquidation of Bophelo Bio Science and Wellness (Pty) Ltd. is still ongoing. The Company is also in the business of sales and distribution of cannabis-based products for medical use, through its subsidiary Canmart Ltd which is based in the UK.

The Company was incorporated for the designed purpose of becoming the ultimate parent company of Cannahealth Ltd. ("Cannahealth"), through a reorganization of entities with common control. The share purchase agreement became unconditional on or about November 3, 2021 and the Company acquired the shares in the aforementioned entities from Halo Collective Inc. ("Halo").

The Company's condensed consolidated financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. Attention is drawn to the fact that the Company incurred a net cash outflow of $8,353,721 from operating activities for the six months ended June 30, 2022. The continuing operations of the Company are dependent upon its ability to raise further cash funding by way of issuing debt and/or equity, as well as its ability to generate cash profits from its investments in Canmart Ltd. and Holigen Ltd. in the near future.

The Company is an early-stage company and is primarily dependent on externally provided financing to continue as a going concern. Additional funds will be required to enable the Company to pursue such an initiative and the Company may be unable to obtain such financing on satisfactory terms. Furthermore, there is no assurance that the Company will be profitable. Management intends to finance operating costs over the next twelve months with its cash on hand, and/or additional cash that will be generated from operations. The Company does not at this stage have any firm plans or commitments regarding further financing.

These uncertainties may cast significant doubt upon the Company's ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities which might be necessary should the Company be unable to continue in existence.

In March 2020, the World Health Organization declared COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company's business or ability to raise funds.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;**2.** **Basis of Preparation** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***(a)***  ***Statement of compliance*** 

These condensed consolidated financial statements, including comparatives, have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC").

These condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard ("IAS") 34 Interim Financial Reporting and have been prepared using the same accounting policies and methods of application as those used in the Company's audited consolidated financial statements for the year ended December 31, 2021. These condensed consolidated interim financial statements do not include all of the information required for full annual consolidated financial statements and should be read in conjunction with the Company's audited consolidated financial statements for the year ended December 31, 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***(b)***  ***Basis of preparation*** 

These condensed consolidated financial statements have been prepared on an accrual basis, except for cash flow information, and are based on the historical cost, modified where applicable and related to the valuation of certain financial assets and financial liabilities to fair value.

Cannahealth and its subsidiaries, Bophelo Holdings Ltd, Bophelo Bio Science and Wellness (Pty) Ltd, and Canmart Ltd were under the common control of Halo until the acquisition by the Company had occurred. As of November 2021, shareholdings in each of the three separate entities were made consistent through the issuance of shares or the repurchase of shares for cash to the relevant shareholders (the 'Reorganization Transactions'). As of November 2021, shareholdings in each of the four entities were identical. When the Company was formed in July 2021 with a view to ultimately acquiring Cannahealth and its subsidiaries, its majority shareholders were also consistent with each of the three existing entities. Therefore, immediately prior to the acquisition, the majority shareholder ownership of the Company and Cannahealth were demonstrated common control, and immediately after the acquisition, the shareholdings held in the Company by each individual shareholder were also identical.

The Company performed an assessment and determined Bophelo Bio Science and Wellness (Pty) Ltd to be the predecessor entity to the Company, and that the corporate restructuring in which Akanda became the parent company did not have economic substance. As such, in preparing the Company's condensed consolidated financial statements, the Company accounted for the acquisition in as a transaction between entities under common control combining the Company and Cannahealth from the earliest reporting date using the 'pooling of interests method' of accounting, where assets for the Companies that came under common control were transferred into the consolidated group at the book value on the date in which common control was achieved.

In the acquisition described above, shares were issued to existing shareholders for no consideration. Therefore, the number of shares outstanding was increased without an increase in resources. The number of shares outstanding before the exchange have been adjusted for the change in shares as if the issuance had occurred at the beginning of the earliest period presented. All share and per share information presented herein has been retrospectively adjusted to give effect to the culmination of the reorganization and the issuance of shares on incorporation of Akanda on January 1, 2019.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***(c)***  ***Functional and presentation currency*** 

These condensed consolidated financial statements are prepared and presented in United States Dollars ("USD" or "$"), which is the Company's reporting currency. All financial information has been rounded to the nearest dollar except where indicated otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***(d)***  ***Use of estimates and judgments*** 

The preparation of consolidated financial statements in conformity with IFRS requires management to make estimates, judgements and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, revenue and expenses during the period. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Areas

in which management has made critical judgments in the process of applying accounting policies and that have the most significant effect on the amounts recognized in the condensed consolidated financial statements include the determination of the Company's and its subsidiaries' functional currencies.

&nbsp;&nbsp;&nbsp;&nbsp;**3.** **New standards issued, not yet adopted** 

In January 2020, the IAS issued an amendment to IAS 1 Presentation of Financial Statements that clarifies the criterion for classifying a liability as non-current relating to the right to defer settlement of a liability for at least 12 months after the reporting period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Liabilities are classified as non-current if the entity has a substantive right to defer settlement for at least 12 months at the end of the reporting period. The amendment no longer refers to unconditional rights. The assessment determines whether a right exists, but it does not consider whether the entity will exercise the right.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.'Settlement' is defined as the extinguishment of a liability with cash, other economic resources or an entity's own equity instruments. There is an exception for convertible instruments that might be converted into equity, but only for those instruments where the conversion option is classified as an equity instrument as a separate component of a compound financial instrument.

The amendment applies to annual reporting periods beginning on or after January 1, 2023 and is applied retrospectively upon adoption. The Company does not expect the amendments to have a significant impact on the condensed consolidated financial statements upon adoption.

&nbsp;&nbsp;&nbsp;&nbsp;**4.** **Business combination** 

On April 29, 2022, the Company, through its wholly owned subsidiary, Cannahealth, acquired 100% of the Ordinary Shares of Holigen Limited ("Holigen") and its wholly-owned operating subsidiary, RPK Biopharma Unipessoal, LDA ("RPK") from the Flowr Corporation. Through its operations in RPK, Holigen is a producer of premium EU GMP grade indoor grown cannabis flower. The acquisition of Holigen enables the Company to immediately have the ability to produce EU GMP grade cannabis flower for the European market. Consideration for the acquisition consisted of a payment of $3,000,000 in cash and 1,900,000 common shares of the Company's share capital.

RPK's operations consist of a 20,000 square foot indoor EU GMP certified grow facility located near Sintra, Lisbon, Portugal, dedicated to the cultivation of high-THC premium cannabis as well as a large seven million square foot (180+ acre) outdoor facility located in Aljustrel, Portugal. Holigen is a Maltese-based entity and provides the added superior genetics, capacity, and route-to-market in the EMEA region, of which the Company intends to augment the Company's current operations.

The following table summarizes the acquisition-date fair value of each major class of purchase consideration that was transferred to the Flowr Corporation in lieu of the acquisition of 100% of the Ordinary Shares of Holigen:

---

| | |
|:---|:---|
| Cash | $2600000 |
| Holdback payable | 400000 |
| Fair value of 1,900,000 common shares of the Company | 16131000 |
| Total consideration transferred | $19131000 |

---

The cash purchase price of the acquisition is $3.0 million, of which $2.6 million has been paid and $400,000 to fund the holdback payable is currently included within cash held in trust at June 30, 2022. The holdback payable represents funds withheld until resolution of a potential liability between the vendor and a service provider, of which the Company expects resolution within the next twelve (12) months. The fair value of the 1,900,000 common shares was based on the fair value of the trading price of the Company's common shares on the Nasdaq Capital Markets exchange of $8.49 per common share on April 29, 2022. Of the equity component of the purchase consideration of 1,900,000 common shares of the Company that was transferred to the Flowr Corporation, an amount of 96,354 common shares was directly transferred to Apolo Capital Advisory, who acted as advisors to the Flowr Corporation in respect of the transaction. The purchase of Holigen has been accounted for by the acquisition method, with the results of Holigen included in the Company's results of operation from the date of acquisition. The purchase of Holigen was determined as being a business combination in accordance with the requirements of IFRS 3 – Business Combinations, due to the fact that the Company acquired control over Holigen on the acquisition date through the purchase of 100% of its voting securities

and consequent transfer of the purchase consideration (set out in the table above) to the sellers of the Holigen, namely the Flowr Corporation.

The Company incurred acquisition-related costs of approximately $250,000 relating to external legal fees, due diligence costs and valuation services. These costs have been included in "consulting and professional fees" expenses in the unaudited condensed consolidated statement of profit or loss for the six months ended June 30, 2022.

The following table summarizes the fair value of the identifiable assets and liabilities as at the date of acquisition:

---

| | |
|:---|:---|
| Cash | $233407 |
| Accounts receivable | 605579 |
| Biological assets | 200457 |
| Inventory | 904006 |
| Prepayments | 179597 |
| Intangible assets | 24665772 |
| Property, plant and equipment, net | 12936374 |
| Trade and other payables | (3775599) |
| Loans and borrowing | (4058030) |
| Net assets acquired | $31891563 |

---

During the six months ended June 30, 2022, the Company recorded a bargain purchase gain of $12,760,563 within other income, representing the fair value of net assets acquired of $31,891,563 in excess of the fair value of consideration of $19,131,000. The fair value of the net asset acquired was determined by an independent valuer using the discounted cash flow method of valuation.

From the date of acquisition, the operations of Holigen contributed a net loss of $814,896 primarily due to the fact that Holigen was substantially in a pre-revenue stage. If the acquisition had taken place on January 1, 2022, the operations of Holigen would have contributed net loss of $1,725,371 for the six months ending June 30, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;**5.** **Loss of control of Bophelo Bio Science andand Wellness (Pty) Ltd.** 

At June 30, 2022, the Company determined that it no longer controlled Bophelo Bio Science and Wellness (Pty) Ltd. as a result of the insolvent liquidation order signed by the Lesotho Court on July 15, 2022 (see note 17). As a result of the loss of control, the Company derecognized all assets and liabilities at their book values on June 30, 2022 and wrote down all balances receivable from the entity to nil. During the six months ended June 30, 2022, the Company recorded a loss on loss of control of Bophelo Bio Science and Wellness (Pty) Ltd. of $2,338,342, which included $800,794 of cash held by Bophelo Bio Science and Wellness (Pty) Ltd. The Company accounted for the operating results of Bophelo Bio Science and Wellness (Pty) Ltd. as a discontinued operation during the six months ended June 30, 2022 and has reclassified the operating results of Bophelo Bio Science and Wellness (Pty) Ltd as a discontinued operation for the six months ended June 30, 2021.

Set out below is the financial performance and cash flow information for the six months ended June 30, 2022 and 2021 related to the discontinued operation:

---

| | | |
|:---|:---|:---|
| **Six months ended June 30** | **2022** | **2021** |
| Revenue | $32802 | $— |
| Operating expenses | (1311825) | (1385676) |
| Other (expense) income | (129669) | (140259) |
|  | (1408692) | (1525935) |
| Loss on loss of control of subsidiary | (2338342) |  |
| Loss on discontinued operation | $(3747034) | $(1525935) |
| Exchange differences on translation of discontinued operations | $(83437) | $(185608) |
| Other comprehensive income from discontinued operations | $(83437) | $(185608) |
| Cash flows provided by (used in) operating activities | $316746 | $(1066276) |
| Cash flows used in investing activities | (213669) | (483580) |
| Cash flows (used in) provided by financing activities | (100857) | 3458087 |
| Effects of exchange rate changes on cash and cash equivalents | (22186) | 25117 |
| Net change in cash (used in) provided by the subsidiary | $(19966) | $1933348 |
| Carrying amount of net assets immediately prior to loss of control of subsidiary | $2571054 |  |
| Reclassification of foreign currency translation reserve | (232712) |  |
| Loss on loss of control of subsidiary | $2338342 |  |

---

As at June 30, 2022, the carrying amounts of assets and liabilities of Bophelo Bio Science and Wellness (Pty) Ltd were as follows:

---

| | |
|:---|:---|
| Cash | $800794 |
| Accounts receivable | 23651 |
| Prepayments | 625606 |
| Property, plant and equipment | 2042641 |
| Right-of-use assets | 1888715 |
| Intangible assets | 227704 |
| Total assets | $5609111 |
| Trade and other payables | 124740 |
| Lease liability | 2570939 |
| Long-term debt | 342378 |
| Total liabilities | $3038057 |
| Net assets | $2571054 |

---

&nbsp;&nbsp;&nbsp;&nbsp;**6.** **Accounts Receivable** 

---

| | | |
|:---|:---|:---|
|  | **June 30**<br>**2022** | **December 31**<br>**2021** |
| Trade accounts receivable | $538988 | $29457 |
| Sales taxes receivable | 38667 | 212900 |
| Other receivables | 149210 |  |
|  | $726865 | $242357 |

---

As at June 30, 2022, there were two customers with an amount greater than 10% of the Company's trade accounts receivable which represented 87% of the balance. As at December 31, 2021, there was one customer with an amount greater than 10% of the Company's trade accounts receivable which represented 94% of the balance. The Company did not record any bad debt expense during the six months ended June 30, 2022 (2021 - nil).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;**7.** **Inventory** 

The Company's inventory included consumer packaging inventory and dried cannabis flower finished product at RPK in Portugal with a total carrying amount of $895,773.67 (2021 - $0). During the six months ended June 30, 2022, inventories with a cost of $34,704 were recorded as cost of sales (2021 - $5,849).

&nbsp;&nbsp;&nbsp;&nbsp;**8.** **Financial asset measured at FVTPL** 

During the six months ended June 30, 2022, concurrent to the acquisition of Holigen (refer to note 4 above), the Company subscribed for, and purchased 14,285,714 ordinary shares of The Flowr Corporation (TSX-V: FLWR) by way of a private placement for a consideration of approximately $801,160 (CDN$1,000,000). The subscription for the 14,285,714 ordinary shares of the Flowr Corporation was a closing deliverable requirement in terms of the sale and purchase agreement between the Company and the Flowr Corporation with respect to the acquisition of Holigen. Set out below is a reconciliation of the movement of the Company's investment during the six months ended June 30, 2022:

---

| | |
|:---|:---|
| Balance, December 31, 2021 | $— |
| Purchase of investment | 801160 |
| Change in fair value | (472311) |
| Movement in exchange rate | 8296 |
| Balance, June 30, 2022 <sup>(\*)</sup> | $337145 |

---

<sup>(\*)</sup> – Reflects closing price of CAD$0.03 on June 30, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;**9.** **Property and Equipment** 

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| <br>**Cost** | <br>**Land** | **Plant**<br>**and**<br>**equipment** | <br>**Leasehold**<br>**Improvements** | <br>**Motor**<br>**Vehicles** | <br>**Computers** | **Furniture**<br>**and**<br>**fixtures** | **Capital**<br>**work-in-**<br>**progress** | <br>**Total** |
| Balance, December 31, 2020 | $— | $586360 | $293437 | $36998 | $— | $— | $883145 | $1799940 |
| Additions |  | 53808 | 493136 | 14214 | 10427 | 4887 |  | 576472 |
| Reclassifications |  |  | 360695 |  |  |  | (360695) |  |
| Foreign exchange movements |  | (50157) | (57574) | (3589) | (303) | (192) | (58197) | (170012) |
| Balance, December 31, 2021 | $— | $590011 | $1089694 | $47623 | $10124 | $4695 | $464253 | $2206400 |
| Acquisitions (note 4) | 872336 | 11817462 |  | 89513 | 32703 | 124360 |  | 12936374 |
| Additions |  | 53561 | 69676 | 11055 | 11683 | 2926 | 114490 | 263391 |
| Impact of loss of control of Bophelo Bio Science and Wellness (Pty) Ltd. |  | (717956) | (1178087) | (59271) | (16072) | (5883) | (473062) | (2450331) |
| Foreign exchange movements | (7945) | (9081) | 18717 | (1096) | (2386) | (1641) | (105681) | (109114) |
| Balance, June 30, 2022 | $864391 | $11733997 | $— | $87824 | $36052 | $124457 | $— | $12846720 |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| <br>**Accumulated**<br>**depreciation** | <br>**Land** | **Plant**<br>**and**<br>**equipment** | <br>**Leasehold**<br>**Improvements** | <br>**Motor**<br>**Vehicles** | <br>**Computers** | **Furniture**<br>**and**<br>**fixtures** | **Capital** <br>**work-in-**<br>**progress** | <br>**Total** |
| Balance, December 31, 2020 | $— | $123710 | $36324 | $13874 | $— | $— | $— | $173908 |
| Depreciation |  | 63785 | 78352 | 11208 | 1245 | 483 |  | 155073 |
| Foreign exchange movements |  | (12641) | (6053) | (1577) | (39) | (19) |  | (20329) |
| Balance, December 31, 2020 | $— | $174854 | $108623 | $23505 | $1206 | $464 | $— | $308652 |
| Depreciation |  | 292407 | 52210 | 14369 | 9789 | 3948 |  | 372723 |
| Impact of loss of control of Bophelo Bio Science and Wellness (Pty) Ltd. |  | (21126) | (161427) | (30689) | (3114) | (947) |  | (217303) |
| Foreign exchange movements |  | (222938) | 594 | (955) | (1732) | (607) |  | (225639) |
| Balance, June 30, 2022 | $— | $223197 | $— | $6230 | $6149 | $2858 | $— | $238433 |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| <br>**Net book value** | <br>**Land** | **Plant**<br>**and**<br>**equipment** | <br>**Leasehold**<br>**Improvements** | <br>**Motor**<br>**Vehicles** | <br>**Computers** | **Furniture**<br>**and**<br>**fixtures** | **Capital**<br>**work-in-**<br>**progress** | <br>**Total** |
| Balance, December 31, 2021 | $— | $415157 | $981071 | $24118 | $8918 | $4231 | $464253 | $1897748 |
| Balance, June 30, 2022 | $864391 | $11510800 | $— | $81594 | $29903 | $121599 | $— | $12608287 |

---

As at June 30, 2022, the Company derecognized property, plant and equipment with a net book value of $2,233,028 in connection with the loss of control of Bophelo Bio Science and Wellness (Pty) Ltd. As at December 31, 2021 and 2020 the Company's Capital

work in progress related to the ongoing civil, gravelling, storm drainage work on site, as well as the construction of hoop houses and a Cravo A-Frame style greenhouse for future medical cannabis cultivation in Bophelo, Lesotho, which was derecognized at June 30, 2022 as a result of the loss of control of Bophelo Bio Science and Wellness (Pty) Ltd.

During the six months ended June 30, 2022, the Company recorded depreciation of its property, plant and equipment of $372,723 (2021 – $70,293) of which $115,890 (2021 – $90,974) related to the operations of Bophelo Bio Science and Wellness (Pty) Ltd was recorded within discontinued operations.

&nbsp;&nbsp;&nbsp;&nbsp;**10.** **Right-of-use Assets** 

---

| | |
|:---|:---|
|  | **Land lease** |
| Balance, December 31, 2020 | $2199779 |
| Additions |  |
| Amortization | (115183) |
| Movement in exchange rates | (175719) |
| Balance, December 31, 2021 | $1908877 |
| Additions |  |
| Amortization | (58010) |
| Impact of loss of control of Bophelo Bio Science and Wellness (Pty) Ltd. | (1888715) |
| Movement in exchange rates | 37848 |
| Balance, June 30, 2022 | $— |

---

During the six months ended June 30, 2022, the Company recorded amortization on its right-of-use assets of $58,010 (2021 - $61,447) within discontinued operations. As at June 30, 2022, the Company derecognized right-of-use assets with a net book value of $1,888,715 in connection with the loss of control of Bophelo Bio Science and Wellness (Pty) Ltd.

&nbsp;&nbsp;&nbsp;&nbsp;**11.** **Intangible Assets** 

---

| | | | |
|:---|:---|:---|:---|
| **Cost:** | **Software** | **Licenses** | **Total** |
| Balance, December 31, 2020 | $— | $422826 | $422826 |
| Movement in exchange rates |  | (33370) | (33370) |
| Balance, December 31, 2021 | $— | $389456 | $389456 |
| Acquisitions | 17548 | 24648225 | 24665773 |
| Impact of loss of control of Bophelo Bio Science and Wellness (Pty) Ltd. |  | (379506) | (379506) |
| Movement in exchange rates | (390) | 5368 | 4978 |
| Balance, June 30, 2022 | $17158 | $24663543 | $24680701 |
| **Accumulated amortization:** | **Software** | **Licenses** | **Total** |
| Balance, December 31, 2020 | $— | $101420 | $101420 |
| Amortization |  | 38766 | 38766 |
| Movement in exchange rates |  | (9832) | (9832) |
| Balance, December 31, 2021 | $— | $130354 | $130354 |
| Amortization | 2370 | 1251935 | 1254305 |
| Impact of loss of control of Bophelo Bio Science and Wellness (Pty) Ltd. |  | (151802) | (151802) |
| Movement in exchange rates | (336) | 1924 | 1588 |
| Balance, June 30, 2022 | $2034 | $1232411 | $1234445 |
| **Net book value** | **Software** | **Licenses** | **Total** |
| Balance, December 31, 2021 | $— | $259102 | $259102 |
| Balance, June 30, 2022 | $15124 | $23431132 | $23446256 |

---

The Company's licenses consist of a cannabis distribution license with a carrying value of $15,318 at June 30, 2022 (December 31, 2021 - $17,016) a cannabis API manufacturing and GMP license with a carrying value of $23,415,814 (December 31, 2021 - $0). As at June 30, 2022, the Company derecognized a cannabis operator's license with a net book value of $227,704 (December 31, 2021 – $242,086) in connection with the loss of control of Bophelo Bio Science and Wellness (Pty) Ltd. The Company considered

indicators of impairment at June 30, 2022 and December 31, 2021. The Company did not record any impairment loss during the six months ended June 30, 2022 (2021 – nil).

At June 30, 2022, the remaining useful life of the Company's finite life intangible assets is approximately 9.5 years. The Company's cannabis distribution license has been classified as an indefinite-life intangible asset as the Company expects to maintain this asset and the end point of the useful life of such asset cannot be determined. The Company evaluates the assumption of the indefinite life of the cannabis distribution license at least annually.

**12.** **Loan Receivable**

---

| | | |
|:---|:---|:---|
|  | **June 30**<br>**2022** | **December 31**<br>**2021** |
| Loan to Cellen Life Sciences Limited | $485272 | $134770 |
|  | $485272 | $134770 |

---

Included in the loan receivable at June 30, 2022 is an amount of $485,272 (December 31, 2021 - $134,770) owed by Cellen Life Sciences Limited to the Company pursuant to a Bridge Loan Arrangement entered into in December 2021. The amount payable to the Company in terms of the Bridge Loan Agreement was subject to a restructuring arrangement entered into by the Company (the Loan Restructuring Agreement) after the end of the reporting period, namely June 30, 2022. Refer to note 18 for further information.

&nbsp;&nbsp;&nbsp;&nbsp;**13.** **Lease Liability** 

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | <br>**Maturity** | **Incremental**<br>**borrowing rate** | **June 30**<br>**2022** | **December 31**<br>**2021** |
| Current | 2022 | 10.25% | $— | $439709 |
| Non-current | 2023-2039 | 10.25% |  | 1978997 |
|  |  |  | $— | $2418706 |

---

As at June 30, 2022, the Company derecognized the lease liability with a net book value of $2,570,939 (December 31, 2021 - $2,418,706) in connection with the loss of control of Bophelo Bio Science and Wellness (Pty) Ltd.

Bophelo Bio Science and Wellness (Pty) Ltd has committed to the following undiscounted minimum lease payments remaining as at June 30, 2022:

---

| | |
|:---|:---|
| **Year ended December 31:** |  |
| 2022 remaining | $110689 |
| 2023 | 265654 |
| 2024 | 265654 |
| 2025 | 265654 |
| 2026 | 265654 |
| Thereafter | 3254264 |
|  | $4427569 |

---

&nbsp;&nbsp;&nbsp;&nbsp;**14.** **Loans Payable** 

&nbsp;&nbsp;&nbsp;&nbsp;*(a)* *Louisa Mojela loans:* 

The loans described below have been granted to the Company to fulfill its capital and operational requirements. The terms of the loans are described below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(i)* *Short-term loan #1* 

This is a short-term loan facility of approximately $135,226 in capital value lent. to assist the Company in funding working capital deficits. This loan was unsecured, repayable within 30 days of receiving the payment and carried interest at the rate linked to the prime lending rate in the Republic of South Africa. The capital balance of this loan was repaid in full before the end of the financial year December 31, 2020. At June 30, 2022, the Company determined that it no longer controlled

Bophelo Bio Science and Wellness (Pty) Ltd. as a result of the insolvent liquidation order signed by the Lesotho Court on July 15, 2022 (see note 17). As a result of the loss of control, the Company derecognized all assets and liabilities at their book values on June 30, 2022 and wrote down this payable to Nil (see Note 5. The unpaid interest balance on this loan as at December 31, 2021 was $9,068.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(ii)* *Short -term loan #2* 

This is a short-term loan facility of approximately $190,444 in capital value lent to assist the Company in funding its day-to-day operating costs. This loan does not have a fixed repayment date, is unsecured and is interest free. At June 30, 2022, the Company determined that it no longer controlled Bophelo Bio Science and Wellness (Pty) Ltd. as a result of the insolvent liquidation order signed by the Lesotho Court on July 15, 2022 (see note 17). As a result of the loss of control, the Company derecognized all assets and liabilities at their book values on June 30, 2022 and wrote down this payable to Nil (see Note 5). The balance on this loan at December 31, 2021 was $174,840

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(iii)* *Short-term loan* 

During the year ended December 31, 2021, the Company received short term loan facility of approximately $258,900 (L 4,000,000) to assist the Company in funding its day-to-day operating costs. At June 30, 2022, the Company determined that it no longer controlled Bophelo Bio Science and Wellness (Pty) Ltd. as a result of the insolvent liquidation order signed by the Lesotho Court on July 15, 2022 (see note 17). As a result of the loss of control, the Company derecognized all assets and liabilities at their book values on June 30, 2022 and wrote down this payable to Nil (see Note 5). As at December 31, 2021 the balance remaining was $248,293. This loan does not have a fixed repayment date, is unsecured and is interest free.

&nbsp;&nbsp;&nbsp;&nbsp;*(b)* *Bank loans* 

The below loans have been granted to Holigen Ltd. and its subsidiaries in order to fund their capital and operational needs on site.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*i.* *Short term loans* 

As at June 30, 2022, the balance of the loans from Caixa was $1,262,785 which consisted of loans for the purpose of building construction and purchase of equipment. The repayment date on these loans are February 22, 2026 and June 5, 2026 respectively. These loans are charged interest at the rate of 3,00% and are secured by mortgage of building and equipment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*ii.* *Long term loans* 

As at June 30, 2022, the balance of the loans from Caixa was $2,570,127 which consisted of loans for the purpose of building construction and purchase of equipment. The repayment date on these loans are February 22, 2026 and June 5, 2026 respectively. These loans are charged interest at the rate of 3,00% and are secured by mortgage of building and equipment.

&nbsp;&nbsp;&nbsp;&nbsp;**15.** **Share Capital** 

&nbsp;&nbsp;&nbsp;&nbsp;***(a)***  ***Authorized*** 

The Company has authorized share capital of an unlimited amount of common shares with no par value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;***(b)***  ***Shares issued and outstanding*** 

---

| | | |
|:---|:---|:---|
| **Cost:** | **Number of shares** | **Capital** |
| Balance, December 31, 2020 | 13129212 | $1636 |
| Shares issued to founders | 5626806 | 1 |
| Seed subscription | 468900 | 250000 |
| Private Placement | 2126400 | 4804058 |
| Settlement of Bridge Loan | 880000 | 2200000 |
| Balance, December 31, 2021 | 22231318 | $7255695 |
| Issuance of shares in Holigen acquisition (note 4) | 1900000 | 16131000 |
| Issuance of shares to ASDT | 869963 | 2174908 |
| Issuance of shares from private placement | 162000 | 278481 |
| Issuance of shares from IPO | 4000000 | 14654593 |
| Issuance of shares upon conversion of note | 1645745 | 6559000 |
| Loss of control of Bophelo Bio |  | (156) |
| Balance, June 30, 2022 | 30809026 | $47053521 |

---

Shares issued and outstanding are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(i)* The 13,129,212 shares issued to Halo in exchange for the Cannahealth acquisition have been deemed to be issued and outstanding as of the earliest reporting date, December 31, 2020.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(ii)* On July 16, 2021, the Company issued 5,626,806 common shares in the Company's capital to its founders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(iii)* On July 26, 2021, the Company completed a seed capital offering issuing 468,900 common shares in the Company's capital at approximately $0.53 per share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(iv)* On November 12, 2021, the Company issued 13,129,212 shares to the former shareholders of Cannahealth Limited to facilitate the acquisition of the entity, at a value of $0.01 per share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(v)* On November 12, 2021, the Company completed a private placement, receiving gross consideration of $5,312,136 upon the issuance of 2,126,400 common shares of the Company at a price of $2.50 per share. The Company paid $508,078 in advisory fees and commissions associated with the offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(vi)* On November 10, 2021, the Company issued 880,000 common shares at a value of $2.50 per common share to settle bridge loans payable of $2,200,000 (Note 10).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(vii)* On March 14, 2022, the Company issued 869,963 common shares to the Akanda Bokamoso Empowerment Trust at a deemed value of $2.50 per common share, the per share value of the concurrent private placement (see (*viii*)). The Company recorded an expense of $2,174,908 within general and administrative expenditures reflecting the cost of the shares issued at nil proceeds. The share based payment to the Akanda Bokamoso Empowerment Trust is a social development initiative of the Company and its beneficiaries are the employees of subsidiaries within the group.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(viii)* On March 14, 2022, the Company completed a private placement, issuing 162,000 common shares upon gross receipts of $405,000 net of issuance costs of $126,519 .

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(ix)* On March 15, 2022, the Company issued 1,645,745 common shares to Halo Collective, Inc. ("Halo") at a price of $4 each to settle the principal amount of $6,559,294 plus accrued interest $23,686 owing to Halo in terms of a convertible debenture agreement, which totaled $6,582,980 at the time of conversion. The conversion of the debt owing was triggered by the Initial Public Offering in terms of the convertible debenture agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(x)* On March 15, 2022, the Company issued 4,000,000 common shares to IPO investors in exchange for gross proceeds of $16,000,000 and net proceeds of $14,682,089 after deducting underwriter commissions and allowable expenses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(xi)* On April 29, 2022, the Company issued 1,900,000 common shares at a fair value of $8.49 per share as part of the consideration in the acquisition of Holigen (Note 4).

&nbsp;&nbsp;&nbsp;&nbsp;***(c)***  ***Earnings per share*** 

The weighted average number of common shares outstanding for basic and diluted earnings per share for the six months ended June 30, 2022 was 26,835,444 (2021 – 13,129,212). The Company did not have any potential dilution during the six months ended June 30, 2022 or 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;***(d)***  ***Restricted stock units*** 

In order to incentivize senior executive management and key staff, the Company makes use of equity incentives awarded pursuant to the Employee Share Ownership Plan ("ESOP"). In terms of the ESOP, the Company may award up to 20% of the Company's issued share capital (at any point in time) in qualifying ESOP incentives.

On April 22, 2022, the Company granted 2,480,532 restricted stock units ("RSUs") to directors, officers, and employees of the Company, of which service cost of $576,340 was included in general and administrative expenses during the six months ended June 30, 2022 (2021 - $0).

&nbsp;&nbsp;&nbsp;&nbsp;**16.** **Related Party Transactions** 

*Secured convertible debenture*

On November 3, 2021 (the "Issuance Date"), the Company entered into an agreement with Halo in which the Company issued Halo a secured convertible debenture with an initial value of $6,559,294. The notes were convertible into common shares of the Company's capital receiving the number of shares, at its current market price, required to satisfy the principal and interest payable. The obligation to convert the note within six months of the Issuance Date is triggered by (a) an initial public offering by the Company on a stock exchange; (b) an amalgamation, arrangement, merger, reverse takeover, reorganization or similar event; (c) a sale or conveyance of all or substantially all of the property and assets of the Company to any arm's length third party for consideration consisting of free trading securities and the subsequent distribution of all of such consideration to all of the holders of common shares, on a pro rata basis; (d) the sale or exchange of all or substantially all of shares of the Borrower for free trading securities. The debt bears interest at one percent per annum, matures on November 3, 2022 and is secured by all of the assets of the Company other than the interests in the securities of Bophelo Bio Science and Wellness (Pty) Ltd. and ranks ahead of all other debt issued by the Company. On March 15, 2022, upon completion of the Company's initial public offering the Company issued 1,645,745 common shares to Halo Collective, Inc. ("Halo") at a price of $4 each to settle the principal amount of $6,559,294 plus accrued interest $23,686 owing to Halo in terms of a convertible debenture agreement, which totaled $6,582,980 at the time of conversion (see note 13(b)(ix)).

*Transactions with Key Management Personnel*

The Company has identified its Board of Directors, Executive Chairman, Chief Executive Officer ("CEO"), Chief Operating Officer ("COO"), Chief Financial Officer ("CFO") and its President as its key management personnel who have the authority and responsibility for planning, directing and controlling the Company's main activities.

---

| | | |
|:---|:---|:---|
| **For the period ended June 30** | **2022** | **2021** |
| Key Management Remuneration | 1079324 | 114235 |
| Stock-based compensation | 487885 |  |
| Short term accommodation expense |  | 35924 |
|  | $1567209 | $150158 |

---

The Key Management remuneration is included in Professional and Consulting fees in the Statement of Operations.

During the period ended June 30, 2021, the Company incurred expenditures of $35,924 associated with rental of short-term accommodation from the Company's executive Chairman, LM Mojela, to house the Company's expatriate staff working on site at the Company's cultivation operation in the Kingdom of Lesotho.

As of June 30, 2022, the Company has balances payable to related parties of $743,188 (December 31, 2021 - $9,601,708) as below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. As at December 31, 2021 the entire balance of Loans and Borrowings of $432,201 (Note 10) was payable to LM Mojela. The balance does not bear interest, is unsecured and does not have a fixed repayment date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Included within accounts payable and accrued liabilities at June 30, 2022 is remuneration payable to key management totaling $743,188 (December 31, 2021 - $34,611), which includes amounts owing to the following directors and officers of the Company:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. $562,792 owing to T Scott (December 31, 2021 - $0);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. $57,550 owing to T Virk (December 31, 2021 - $0);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. $25,875 owing to T Flow (December 31, 2021 - $0);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. $24,386 owing to Dr. Akkar-Schenkl (December 31, 2021 - $0);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;v. $15,944 owing to L Mojela (December 31, 2021 - $0);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vi. $8,010 owing to P van den Berg (December 31, 2021 - $0);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vii. $6,638 owing to C Kié (December 31, 2021 - $0);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;viii. $1,800 owing to G Jones (December 31, 2021 - $0);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ix. $1,800 owing to G Dingaan (December 31, 2021 - $0); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;x. $1,800 owing to B Baker (December 31, 2021 - $0);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. As at December 31, 2021 the balance of the Company's lease liability (Note 12) pertained to the amount owing to Mophuthi Trust, a Trust controlled by Louisa Mojela and Granny Seape, a director of a subsidiary of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. The balance of the secured convertible debentures as at December 31, 2021 with a carrying value of $6,716,190 bore interest at 1 % per annum.

The Company's related party transactions are measured at the exchange amount which is the amount of consideration established and agreed to by the related parties.

&nbsp;&nbsp;&nbsp;&nbsp;**17.** **Segmented Information** 

The Company has three reportable segments: Cultivation, Distribution & Corporate. Cultivating activities which comprise the "cultivation" segment are made up of the medical cannabis cultivation operations at RPK/Holigen in Portugal, and medical cannabis cultivation activities which were undertaken at Bophelo Bio Science & Wellness (Pty) Ltd in Lesotho up until the loss of control event which occurred in July 2022 when the liquidation of Bophelo Bio Science and Wellness (Pty) Ltd was ordered by the High Court of Lesotho (refer to note 5). Distributing activities relate to the distribution of medical cannabis by Canmart Ltd in the United Kingdom. Corporate activities entail head office costs and other general corporate expenses related to the administration of the broader group. The accounting policies of the operating segments are the same as those described in the summary of significant accounting policies. The reportable segments have been determined by management on the basis that these are strategic business units that offer different products and services. The business units in Portugal and Lesotho (up until the loss of control event described in note 5) which fall under the cultivation segment are focused on the cultivation of medical cannabis and medical cannabis biomass respectively, while the business unit in the United Kingdom, which falls under the distribution segment, undertakes the sale and distribution of medical cannabis products. The corporate segment undertakes management and treasury services within the group and for the benefit of all group companies. They are managed separately as each business unit requires different strategies, risk management and technologies.

Set out below is information about the assets and liabilities as at June 30, 2022 and December 31, 2021 and profit or loss from each segment for the six months ended June 30, 2022 and 2021:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As at June 30, 2022** | **As at June 30, 2022** | **As at June 30, 2022** | **As at June 30, 2022** |
| **Financial statement line item:** | **Cultivation** | **Distribution** | **Corporate** | **Total** |
| Reportable segment assets | $37990837 | $4297366 | $1194078 | $43482281 |
| Reportable segment liabilities | 6494334 | 379982 | 1967505 | 8841821 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As at December 31, 2021** | **As at December 31, 2021** | **As at December 31, 2021** | **As at December 31, 2021** |
| **Financial statement line item:** | **Cultivation** | **Distribution** | **Corporate** | **Total** |
| Reportable segment assets | $4127138 | $3716771 | $205797 | $8043909 |
| Reportable segment liabilities | 3020730 | 323129 | 6899644 | 10243143 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the six months ended June 30, 2022** | **For the six months ended June 30, 2022** | **For the six months ended June 30, 2022** | **For the six months ended June 30, 2022** |
| **Financial statement line item:** | **Cultivation** | **Distribution** | **Corporate** | **Total** |
| Revenues from external customers | $57516 | $15580 | $— | $73096 |
| Intersegment revenues |  |  |  |  |
| Other income (expense) | 12760356 | (6600) | (646494) | 12107262 |
| Finance income |  | 747 |  | 747 |
| Finance expense | (23177) | (52) | (13377) | (36606) |
| Depreciation and amortization | 1511138 |  |  | 1511138 |
| Discontinued operations | (3747034) |  |  | (3747034) |
| Reportable segment income (loss) | 5744346 | (6867849) | (1470241) | (2593744) |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the six months ended June 30, 2021** | **For the six months ended June 30, 2021** | **For the six months ended June 30, 2021** | **For the six months ended June 30, 2021** |
| **Financial statement line item:** | **Cultivation** | **Distribution** | **Corporate** | **Total** |
| Revenues from external customers | $— | $3935 | $— | $3935 |
| Intersegment revenues |  |  |  |  |
| Other expense |  | (914) |  | (914) |
| Finance income |  |  |  |  |
| Finance expense |  |  |  |  |
| Depreciation and amortization |  |  |  |  |
| Discontinued operations | (1525935) |  |  | (1525935) |
| Reportable segment loss | (1525935) | (146417) |  | (1672352) |

---

Set out below are reconciliations of each reportable segment's revenues, profit or loss, assets and liabilities as at June 30, 2022 and December 31, 2021, and for the six months ended June 30, 2022 and 2021:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the six months ended June 30, 2022** | **For the six months ended June 30, 2022** | **For the six months ended June 30, 2022** | **For the six months ended June 30, 2022** |
| **Revenues** | **Cultivation** | **Distribution** | **Corporate** | **Total** |
| Total revenues | $57516 | $15580 | $— | $73096 |
| Elimination of inter segment revenue |  |  |  |  |
| **Total revenue** | $57516 | $15580 | $— | $73096 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the six months ended June 30, 2021** | **For the six months ended June 30, 2021** | **For the six months ended June 30, 2021** | **For the six months ended June 30, 2021** |
| **Revenues** | **Cultivation** | **Distribution** | **Corporate** | **Total** |
| Total revenues | $— | $3935 | $— | $3935 |
| Elimination of inter segment revenue |  |  |  |  |
| **Total revenue** | $— | $3935 | $— | $3935 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the six months ended June 30, 2022** | **For the six months ended June 30, 2022** | **For the six months ended June 30, 2022** | **For the six months ended June 30, 2022** |
| **Loss** | **Cultivation** | **Distribution** | **Corporate** | **Total** |
| Total profit or loss for reportable segments | $9491380 | $(6867849) | $(1470241) | $1153290 |
| Elimination of inter segment profit or loss |  |  |  |  |
| Income (Loss) before income tax expense | $9491380 | $(6867849) | $(1470241) | $1153290 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the six months ended June 30, 2021** | **For the six months ended June 30, 2021** | **For the six months ended June 30, 2021** | **For the six months ended June 30, 2021** |
| **Loss** | **Cultivation** | **Distribution** | **Corporate** | **Total** |
| Total profit or loss for reportable segments | $— | $(146417) | $— | $(146417) |
| Elimination of inter segment profit or loss |  |  |  |  |
| Loss before income tax expense | $— | $(146417) | $— | $(146417) |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As at June 30, 2022** | **As at June 30, 2022** | **As at June 30, 2022** | **As at June 30, 2022** |
| **Assets** | **Cultivation** | **Distribution** | **Corporate** | **Total** |
| Total assets for reportable segments | $37990837 | $23428366 | $14323290 | $75742493 |
| Elimination of inter segment assets |  | (19131000) | (13129212) | (32260212) |
| Segment assets | $37990837 | $4297366 | $1194078 | $43482281 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As at December 31, 2021** | **As at December 31, 2021** | **As at December 31, 2021** | **As at December 31, 2021** |
| **Assets** | **Cultivation** | **Distribution** | **Corporate** | **Total** |
| Total assets for reportable segments | $4048831 | $4082801 | $26031644 | $34163276 |
| Elimination of inter segment assets |  | (366030) | (25825848) | (26191878) |
| Segment assets | $4048831 | $3716771 | $205796 | $7971398 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As at June 30, 2022** | **As at June 30, 2022** | **As at June 30, 2022** | **As at June 30, 2022** |
| **Liabilities** | **Cultivation** | **Distribution** | **Corporate** | **Total** |
| Total liabilities for reportable segments | $15419213 | $31390180 | $(31094865) | $15714528 |
| Elimination of inter segment liabilities | (8924879) | (31010198) | 33062370 | (6872699) |
| Entity's liabilities | $6494334 | $379982 | $1967505 | $8841829 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As at December 31, 2021** | **As at December 31, 2021** | **As at December 31, 2021** | **As at December 31, 2021** |
| **Liabilities** | **Cultivation** | **Distribution** | **Corporate** | **Total** |
| Total liabilities for reportable segments | $10602945 | $5437189 | $6899644 | $22939778 |
| Elimination of inter segment liabilities | (7582575) | (5114060) |  | (12696635) |
| Entity's liabilities | $3020370 | $323129 | $6899644 | $10243143 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;**18.** **Subsequent Events** 

*Liquidation of Bophelo Bio Science and Wellness (Pty) Ltd*

On July 26, 2022, the Company announced that the High Court of Lesotho (the "Lesotho Court") has placed in liquidation the Company's, wholly-owned subsidiary, Bophelo Bio Science and Wellness (Pty) Ltd. ("Bophelo"). The action to place Bophelo in liquidation was taken by the Lesotho Court pursuant to an application and request (the "Liquidation Application") that was filed by Louisa Mojela, the former Executive Chairman of the Company, who was recently terminated as Executive Chairman of Akanda, and the Mophuti Matsoso Development Trust ("MMD Trust"). Akanda intends to convene a special committee to investigate Ms. Mojela's actions and conduct, including actions and conduct taken by her prior to her filing of the Liquidation Application, and will pursue all of its available legal rights and remedies against Ms. Mojela and the MMD Trust for taking this unauthorized action. The Company also intends to contest and seek to reverse the determination by the Lesotho Court to place Bophelo in liquidation. In addition, Akanda will seek to recover significant loans that it has made to Bophelo to fund the execution of Bophelo's business plan, including payment of rents and staffing costs, in the event that the Lesotho Court does not reverse its determination to place Bophelo in liquidation. Finally, Ms. Mojela has been summarily terminated as Chairman of Bophelo for Cause, as a "bad leaver", as a result of her action to seek to place Bophelo in liquidation. Ms. Mojela has instituted legal proceedings against the Company as a result of the termination of her employment. In an action taken without the Company's knowledge, the Lesotho Court has ordered an insolvent liquidation of Bophelo, and has appointed Mr. Chavonnes Cooper of Cape Town, South Africa, as liquidator of Bophelo for purposes of maintaining the value of the assets owned or managed by Bophelo. The order was signed by the Honorable Mr. Justice Mokhesi on July 15, 2022. As a result, the Company deemed that at June 30, 2022 control of Bophelo had been lost and the assets and liabilities of the entity were deconsolidated, resulting in a loss of $2,338,342 (see note 5).

*Nasdaq Minimum Bid Price Requirement Notification*

On October 3, 2022, the Company announced it has received a written notification (the "Notification Letter") on September 27, 2022 from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). It resulted from the fact that the closing bid price of the Company's common shares, no par value ("Common Shares"), was below $1.00 per share for a period of 30 consecutive business days. The Notification Letter does not impact the Company's listing on the Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until March 27, 2023, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company's common shares must have a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by March 27, 2023, the Company may be eligible for additional time to regain compliance or may face delisting.

*Grant of Restricted Share Units ("RSUs") and Consultancy Arrangements*

Subsequent to June 30, 2022, the Company granted 4,503,514 RSUs to directors and consultants.

Subsequent to June 30, 2022, the Board of Directors of the Company approved the following consulting agreements:

---

| | |
|:---|:---|
| ◾ | $300,000 payable to Daniel Petrov for consulting services to be provided to the Company; |

---

---

| | |
|:---|:---|
| ◾ | $300,000 payable to Mehrdad Momeni for consulting services to be provided to the Company; |

---

---

| | |
|:---|:---|
| ◾ | $300,000 payable to Kelly Abbott for consulting services to be provided to the Company; |

---

---

| | |
|:---|:---|
| ◾ | $250,000 payable to Connor Yuen for consulting services to be provided to the Company; |

---

---

| | |
|:---|:---|
| ◾ | $350,000 payable to Suzette Ramcharan for consulting services to be provided to the Company; |

---

---

| | |
|:---|:---|
| ◾ | $450,000 payable to Pouya Farmand for consulting services to be provided to the Company; |

---

◾ 600,000 RSUs payable to Kiran Sidhu for consulting services to be provided to the Company; and

---

| | |
|:---|:---|
| ◾ | $250,000 payable to Terry Booth for advisory work to be provided to the Company. |

---

Following the entering into of the above agreements, Mr. Booth was paid in cash on September 7, 2022, Mr. Sidhu was settled through a grant of RSUs on November 21, 2022, while the remaining consultants were settled through a grant of RSUs that were issued between July 29, 2022 and August 18, 2022, as follows:

◾ Daniel Petrov – 306,123 RSUs which vested on July 29, 2022;

◾ Kelly Abbott – 306,123 RSUs which vested on July 29, 2022;

◾ Mehrdad Momeni – 306,123 RSUs which vested on July 29, 2022;

◾ Connor Yuen – 281,532 RSUs which vested on July 29, 2022;

◾ Suzette Ramcharan – 281,532 RSUs which vested on August 18, 2022; and

◾ Pouya Farmand – 608,108 RSUs which vested on September 6, 2022.

*Cellen Loan Restructuring Agreement*

On November 10, 2022, the Company entered into an agreement (the "Loan Restructuring Agreement") with Cellen Life Sciences Limited and Cellen Biotech Limited (collectively referred to as "Cellen") which entails the restructuring of the payment terms applicable to the $500,000 loan payable by Cellen to the Company pursuant to a Bridge Loan Facility Agreement previously entered into on or around December 2, 2021. In terms of the Loan Restructuring Agreement, Cellen shall repay the $500,000 by no later than the fourth anniversary of the Loan Restructuring Agreement, namely by November 10, 2026. The loan shall not bear interest until the 2nd anniversary (namely November 10, 2024) of the Loan Restructuring Agreement, where thereafter, it shall bear interest at a rate of 5% per annum on the principal amount of the loan ($500,000). The loan is secured over the assets of Cellen.

*Termination Agreement with the Company's President*

Subsequent to June 30, 2022, the Company entered into a termination agreement with the Company's then President, Dr. Aslihan Akkar-Schenkl. In terms of the termination agreement, the existing employment arrangement with Dr. Akkar-Schenkl terminated on September 30, 2022. In lieu of the termination, Dr. Akkar-Schenkl was entitled to receive her contractually agreed bonus of €46,000 and further receive 110,000 common shares of the Company.

*Cansativa Supply Agreement*

On August 8, 2022, the Company (through its subsidiary company RPK) entered into a supply agreement with Cansativa GmbH. In terms of the supply agreement, which is expected to see RPK deliver at least 1,000 kilograms of dried cannabis flower to Cansativa over the first 12-month term of the agreement.